Literature DB >> 21789614

Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?

Omer Kilic1, Ozgur Kasapcopur, Yildiz Camcioglu, Haluk Cokugras, Nil Arisoy, Necla Akcakaya.   

Abstract

To determine the incidence of latent tuberculosis infection and evaluate the follow-up protocol of the patients diagnosed with juvenile idiopathic arthritis (JIA) and other chronic rheumatologic diseases treated with anti-TNF-α treatment (etanercept, infliximab, adalimumab) in Turkey, 144 patients were evaluated retrospectively for the development of tuberculosis. Patients were evaluated every 6 months for tuberculosis using history, physical examination, tuberculin skin test (TST), chest radiographs, and, when required, examination of sputum/early morning gastric aspirates for acid-fast bacilli and chest tomography. A tuberculin skin test over 10 mm induration was interpreted as positive. Patients were diagnosed with JIA (n = 132), enthesitis-related arthritis (ERA; n = 14), juvenile psoriatic arthritis (JPsA; n = 4), chronic idiopathic uveitis (n = 4), and chronic arthritis related to FMF (n = 8). Mean age was 12.25 ± 3.96 years (4.08-19.41 years), mean duration of illness was 5.86 ± 3.77 years (0.66-15 years), and the mean duration of anti-TNF-α treatment was 2.41 ± 1.47 years (0.6-7 years). Anti-TNF-α agents prescribed were etanercept (n = 133), infliximab (n = 30), and adalimumab (n = 6). When unresponsive to one anti-TNF-α therapy, patients were switched to another. There was no history of contact with individuals having tuberculosis. During follow-up, seven patients (4.8%) with positive TST were given INH prophylaxis. One oligoarticular JIA patient (0.69%) diagnosed with secondary uveitis who had been followed for 5 years and had been using infliximab for 2 years, developed a positive Quantiferon-TB test while on INH prophylaxis. He was started on an anti-tuberculosis drug regimen. In conclusion, anti-TNF-α treatment in children with chronic inflammatory disease is safe. Follow-up every 6 months of children on anti-TNF-α treatment with respect to tuberculosis by the pediatric infectious disease department is important to prevent possible complications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21789614     DOI: 10.1007/s00296-011-2030-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  23 in total

Review 1.  Physiology of cytokine pathways in rheumatoid arthritis.

Authors:  W P Arend
Journal:  Arthritis Rheum       Date:  2001-02

2.  Granulomatous infections due to tumor necrosis factor blockade: correction.

Authors:  Robert S Wallis; Michael Broder; John Wong; David Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-10-15       Impact factor: 9.079

Review 3.  Juvenile idiopathic arthritis.

Authors:  Jennifer E Weiss; Norman T Ilowite
Journal:  Pediatr Clin North Am       Date:  2005-04       Impact factor: 3.278

Review 4.  Tuberculosis associated with therapy against tumor necrosis factor alpha.

Authors:  Kevin L Winthrop; Jeffrey N Siegel; John Jereb; Zachary Taylor; Michael F Iademarco
Journal:  Arthritis Rheum       Date:  2005-10

5.  Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy.

Authors:  Urban Sester; Heike Junker; Tobias Hodapp; Alexandra Schütz; Bernhard Thiele; Andreas Meyerhans; Hans Köhler; Martina Sester
Journal:  Nephrol Dial Transplant       Date:  2006-08-25       Impact factor: 5.992

Review 6.  BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment.

Authors: 
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

Review 7.  The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy.

Authors:  Florence Tubach; Dominique Salmon-Céron; Philippe Ravaud; Xavier Mariette
Journal:  Joint Bone Spine       Date:  2005-10-25       Impact factor: 4.929

8.  Purified protein derivative response in juvenile idiopathic arthritis.

Authors:  Evrim Kiray; Ozgur Kasapcopur; Vedat Bas; Ayla Kamburoglu-Goksel; Kenan Midilli; Nil Arisoy; Yucel Tastan
Journal:  J Rheumatol       Date:  2009-07-31       Impact factor: 4.666

9.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Authors:  R S Wallis; M S Broder; J Y Wong; M E Hanson; D O Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-04-15       Impact factor: 9.079

10.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

Authors:  Juan J Gómez-Reino; Loreto Carmona; Vicente Rodríguez Valverde; Emilio Martín Mola; Maria Dolores Montero
Journal:  Arthritis Rheum       Date:  2003-08
View more
  11 in total

1.  Incidence of herpes zoster infections in juvenile idiopathic arthritis patients.

Authors:  S Nimmrich; G Horneff
Journal:  Rheumatol Int       Date:  2015-01-13       Impact factor: 2.631

Review 2.  Treatment in juvenile rheumatoid arthritis and new treatment options.

Authors:  Özgür Kasapçopur; Kenan Barut
Journal:  Turk Pediatri Ars       Date:  2015-03-01

3.  Assessment of tuberculosis infection during treatment with biologic agents in a BCG-vaccinated pediatric population.

Authors:  Basak Yildiz Atikan; Cengiz Cavusoglu; Merve Dortkardesler; Betul Sozeri
Journal:  Clin Rheumatol       Date:  2014-12-18       Impact factor: 2.980

4.  A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors.

Authors:  Heather M Walters; Nancy Pan; Thomas J A Lehman; Alexa Adams; Wei-Ti Huang; Lemonia Sitaras; Susanna Cunningham-Rundles; Thomas J Walsh; Sima S Toussi
Journal:  Clin Rheumatol       Date:  2014-09-18       Impact factor: 2.980

5.  Screening for Latent Tuberculosis in Children With Immune-mediated Inflammatory Diseases Treated With Anti-tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests.

Authors:  Saniye Gİrİt; Ayşe Ayzit Atabek; Ebru Şenol; Tuba KoÇkar Kizilirmak; Sevgi Pekcan; Şafak GÖktaŞ; Sedat Öktem; Özgür KasapÇopur; Haluk ÇokuĞraŞ
Journal:  Arch Rheumatol       Date:  2019-06-25       Impact factor: 1.472

Review 6.  Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions.

Authors:  Katherine Anne B Marzan
Journal:  Adolesc Health Med Ther       Date:  2012-06-20

7.  Juvenile Idiopathic Arthritis.

Authors:  Kenan Barut; Amra Adrovic; Sezgin Şahin; Özgür Kasapçopur
Journal:  Balkan Med J       Date:  2017-04-05       Impact factor: 2.021

8.  Tuberculosis in Children with Rheumatic Diseases Treated with Biologic Disease-Modifying Anti-Rheumatic Drugs.

Authors:  Chengappa Kavadichanda; M B Adarsh; Sajal Ajmani; Ilaria Maccora; S Balan; A V Ramanan; Vikas Agarwal; Latika Gupta
Journal:  Mediterr J Rheumatol       Date:  2021-12-27

Review 9.  Clinical utility of etanercept in the treatment of arthritides in children and adolescents.

Authors:  Robin K Dore
Journal:  Adolesc Health Med Ther       Date:  2014-03-26

10.  Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study.

Authors:  Joan Calzada-Hernández; Jordi Anton-López; Rosa Bou-Torrent; Estíbaliz Iglesias-Jiménez; Sílvia Ricart-Campos; Javier Martín de Carpi; Vicenç Torrente-Segarra; Judith Sánchez-Manubens; Clara Giménez-Roca; Librada Rozas-Quesada; Maria Teresa Juncosa-Morros; Clàudia Fortuny; Antoni Noguera-Julian
Journal:  Pediatr Rheumatol Online J       Date:  2015-12-03       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.